Post-transfusion red cell alloimmunisation in patients with acute disorders and medical emergencies

Revista Brasileira de Hematologia e Hemoterapia

Francisco W. R. Santos²  Silvia Maria M. Magalhães¹  Rosa Maria S. Mota¹  Maria Helena Pitombeira¹ 

[1] ,Federal University of Ceará Instituto Dr. José Frota ,Brazil

关键词: Allo-antibodies;    alloimmunisation;    red cell;    transfusion;    Aloanticorpos;    aloimunização;    eritrócitos;    transfusão;   

DOI  :  10.1590/S1516-84842007000400009

来源: SciELO

【 摘 要 】

Alloimmunisation following red cell transfusion is a complication in patients with chronic diseases requiring multiple transfusions. The aim of this study was to determine the frequency of alloimmunisation, to identify involved alloantibodies, to establish risk factors and to quantify the alloimmunisation risk in patients with acute disorders who received red cell transfusion at the Instituto Dr. José Frota from January 1999 to January 2001. Of the 5,690 recipients who received 16,547 units of red blood cells, 4,025 were men and 1,665 were women. Recipients with previous alloimmunisation or with time of hospital stay less than one week were excluded (n = 501). Red cell alloantibodies were detected in 120 recipients (2.1%): 60 men (1.49%) and 60 women (3.60%). Alloimmunisation was 2.4 fold more frequent in women and 93.33% of the women were pregnant prevously. The average number of units transfused in the alloimmunised recipients was 4.68: 4.97 units in men and 4.40 units in women. In non-alloimmunised recipients the average was 2.87 units and the risk of alloimmunisation was 0.83%: 0.59% in men and 1.44% in women. The most frequent allo-antibodies were: anti-E (18.25%) and anti-D (16.06%) from a total of 137 allo-antibodies detected. The median time for detection of allo-antibodies was 20.88 days. The risk of alloimmunisation detected was high considering the average number of units transfused. The age of recipients and the longer life expectancy increase the probability of further transfusion requirements in this group. Our findings point out the necessity of modifications in the current medical transfusion support indication, including in patients with acute disorders in order to prevent alloimmunisation.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License